Marshall Wace’s Acrivon Therapeutics ACRV Stock Holding History

Marshall Wace’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$779K	Buy	560,436 +64,355	+13%	+$112K	﹤0.01%	2248
2025 Q4	$1.2M	Buy	496,081 +346,366	+231%	+$753K	﹤0.01%	1843
2025 Q3	$271K	Sell	149,715 -31,472	-17%	-$44.2K	﹤0.01%	2468
2025 Q2	$216K	Sell	181,187 -269,204	-60%	-$369K	﹤0.01%	2440
2025 Q1	$914K	Sell	450,391 -147,403	-25%	-$794K	﹤0.01%	1822
2024 Q4	$3.6M	Sell	597,794 -212,065	-26%	-$1.54M	﹤0.01%	1208
2024 Q3	$5.67M	Sell	809,859 -139,007	-15%	-$1.1M	0.01%	947
2024 Q2	$5.5M	Buy	948,866 +351,397	+59%	+$2.83M	0.01%	957
2024 Q1	$4.27M	Hold	597,469	–	–	0.01%	1060
2023 Q4	$2.94M	Hold	597,469	–	–	0.01%	1082
2023 Q3	$5.71M	Hold	597,469	–	–	0.01%	823
2023 Q2	$7.74M	Hold	597,469	–	–	0.02%	845
2023 Q1	$7.58M	Sell	597,469 -625,783	-51%	-$10.5M	0.02%	812
2022 Q4	$14.1M	Buy	+1,223,252	New	+$15.5M	0.03%	624

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace's ACRV Position: Q1 2026 in Review

Marshall Wace increased its Acrivon Therapeutics (ACRV) stake by 13% in Q1 2026, buying an estimated $112K and bringing the position to 560,436 shares worth $779K. The position accounts for ﹤0.01% of the portfolio, ranked #2248.

Marshall Wace first reported a position in ACRV in Q4 2022 and has held it in 14 quarters since. The position peaked at $14.1M in Q4 2022. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Marshall Wace held 560,436 shares of Acrivon Therapeutics worth $779K as of Q1 2026.
Marshall Wace bought 64,355 Acrivon Therapeutics shares in Q1 2026, an estimated $112K.
Acrivon Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2248 holding.
Marshall Wace first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 14 quarters since.
Marshall Wace's Acrivon Therapeutics position peaked at $14.1M in Q4 2022.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.